Drug Discovery and Development: Page 2

Twist Bioscience, Sophia Genetics partner on NGS, DNA analysis

South San Francisco, CA-based Twist has developed a DNA synthesis platform that involves manufacturing synthetic DNA for use in NGS preparation and the development of antibody libraries that inform drug discovery. Sophia Genetics, which has offices in the U.S., Switzerland, and France, has developed an AI-powered platform for DNA analysis.

February 25, 2020

Fusion Genomics secures $1M U.S. to study respiratory infections panel

The Consortium Québécois sur la Découverte du Medicament (CQDM) is a Montreal-based biomedical research consortium that funds new technologies with potential value in facilitating drug discovery and development. The organization noted that since it was founded in 2008, it has raised more than $118 million Canadian ($90 million U.S.) through Canadian government programs and a wide range of pharmaceutical industry partners, including Merck, Pfizer, AstraZeneca, and Eli Lilly.

January 9, 2020

MilliporeSigma licenses CRISPR tech to Promega

Promega will use MilliporeSigma's CRISPR genome-editing technology to create research products and services, including those for drug development.

December 19, 2019

Amgen enlists Adaptive's clonoSeq in broad blood cancer deal

MRD-negativity is an increasingly important marker of treatment response in cancer drug development. Per the deal, Adaptive will provide MRD testing and analysis to inform Amgen's drug development and receive annual development fees, sequencing payments, and milestone payments.

September 18, 2019

Beckman Coulter buys acoustic liquid handling firm Labcyte

Labcyte is known for Echo, an acoustic droplet ejection technology that uses sound waves to transfer minute amounts of liquid with speed and accuracy. Incorporated into the company's Echo Liquid Handlers line of products, the technology enables more efficient lab workflow for applications such as drug discovery and genomics.

January 30, 2019